Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Tafasitamab (Minjuvi)

Published October 13, 2022

Key Messages

  • CADTH recommends that Minjuvi, in combination with lenalidomide, not be reimbursed by public drug plans for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
  • The clinical evidence reviewed by CADTH was not strong enough to show whether treatment with Minjuvi in combination with lenalidomide benefits patients with R/R DLBCL. It is not known if Minjuvi in combination with lenalidomide would lead to better outcomes for patients compared to currently available treatments.
  • Patients identified a need for treatments that prolong survival and remission, control disease symptoms, improve health-related quality of life (HRQoL), and have fewer side effects compared to current therapies. It is not clear whether Minjuvi in combination with lenalidomide meets these needs.